Regeneron Pharmaceuticals Inc. (REGN) announced positive results from late-stage trials on September 17, 2025. In the Phase 2 COURAGE obesity trial, the combination of semaglutide and trevogrumab reduced fat mass by up to 27.1%. Additionally, the Phase 3 Optima trial of garetosmab for fibrodysplasia ossificans progressiva showed a 94% reduction in new bone lesions versus placebo. The company plans to expand testing to pediatric patients next year.

Read more at Yahoo Finance: Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials